Mostrando 9 resultados de: 9
Filtros aplicados
Subtipo de publicación
Article(9)
Publisher
New England Journal of Medicine(2)
American Heart Journal(1)
Canadian Journal of Cardiology(1)
Circulation(1)
Diabetes Care(1)
Basal insulin and cardiovascular and other outcomes in dysglycemia
ArticleAbstract: Background: The provision of sufficient basal insulin to normalize fasting plasma glucose levels mayPalabras claves:Autores:Abdallah A., Ahmad S., AHUAD GUERRERO R.A., Alebuena A., Alvarez N., Alzogaray M., Amuchastegui M., Andres M., Angos M., Avezum A.J., Baglivo H., Bahit M.C., Barbieri M., Bassi F., Bello F., Birkeland K.I., Bogaty P.M., Bono J., Bordeleau L., Bosch J.J., Budaj A.J., Bustamante Labarta M., Bustos B., Cardona E., Chacόn C., Chandra J., Chandra R., Chazova I.E., Commerford P.J., Corson M., Cukierman-Yaffee T., Dagenais G.R., Danilova L., Davies M., Díaz R., Dyal L., Fernando R., Fodor G.J., Gerstein H.C., Gilbert R., Gomis R., Halon D., Hâncu N., Hanefeld M., Harper W.L., Hildebrandt P., Johnston P., Joldersma L., Jung H., Kacerovsky-Bielesz G., Keltai M., Kim J.H., Krum H., Kultursay H., Lanas F.T., Lewis B.S., Lonn E.M., MacRae L., MacRae S., Maggioni A.P., Magloire P., Malik S., Mann J.F.E., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mead A., Mendoza I., Morillo C.A., Pan C., Pasha F., PATRICIO LOPEZ -JARAMILLO, Pavlova V., Pazmino-Canizares J., Pirags V., Pogue J., Pohl K., Probstfield J.L., Profozic V., Punthakee Z., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rydén L.E., Sakalas A., Silva J., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Tsang B., Tyrwhitt J., Vige R., Yakubovich N., Yale J.F., Yusuf S.Fuentes:scopusBleeding and New Cancer Diagnosis in Patients With Atherosclerosis
ArticleAbstract: BACKGROUND: Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be thePalabras claves:aspirin, hemorrhage, neoplasms, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Connolly S.J., Cook-Bruns N., Eikelboom J.W., Felix Camilo, Fox K.A.A., Hart R.G., Maggioni A.P., Moayyedi P., O’Donnell M., Rydén L.E., Shestakovska O., Verhamme P.B., Widimsky P., Yusuf S., Zhu J.Fuentes:googlescopusCardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE)
ArticleAbstract: OBJECTIVE: The Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial reported neutralPalabras claves:Autores:Abdallah A., Ahmad S., AHUAD GUERRERO R.A., Alebuena A., Alvarez N., Alzogaray M., Amuchastegui M., Andres M., Angos M., Avezum A.J., Baglivo H., Bahit M.C., Barbieri M., Bassi F., Bello F., Birkeland K.I., Bogaty P.M., Bono J., Bordeleau L., Bosch J.J., Budaj A.J., Bustamante Labarta M., Bustos B., Cardona E., Chacόn C., Chandra J., Chandra R., Chazova I.E., Commerford P.J., Corson M., Cukierman-Yaffee T., Dagenais G.R., Danilova L., Davies M., DIaz R., Dyal L., Fernando R., Fodor G.J., Gerstein H.C., Gilbert R., Gomis R., Halon D., Hâncu N., Hanefeld M., Harper W.L., Hildebrandt P., Johnston P., Joldersma L., Jung H., Kacerovsky-Bielesz G., Keltai M., Kim J.H., Krum H., Kultursay H., Lanas F., Lewis B.S., Lonn E.M., MacRae L., MacRae S., Maggioni A.P., Magloire P., Malik S., Mann J.F.E., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mead A., Mendoza I., Morillo C.A., Pan C., Pasha F., PATRICIO LOPEZ -JARAMILLO, Pavlova V., Pazmino-Canizares J., Pirags V., Pogue J., Pohl K., Probstfield J.L., Profozic V., Punthakee Z., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rydén L.E., Sakalas A., Silva J., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Tsang B., Tyrwhitt J., Vige R., Yakubovich N., Yale J.F., Yusuf S.Fuentes:scopusCardiovascular efficacy and safety of bococizumab in high-risk patients
ArticleAbstract: BACKGROUND Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilPalabras claves:Autores:Abbott J.D., Amarenco P., Anderson P., Baultrukonis D., Black H., Blake G., Borer J.S., Brunell R., Buonanno M., Carmena R., Chakrabarti A., Chaudhuri S., Chun H., Civeira F., Colquhoun D., Conde D., Cortada J.B., Curto M., Dan G.A., Dearborn-Tomazos J., Edes I., Epsley C., Evans B., Flather M., Foody J., Frederich R., Frolova M., Furie K.L., Gao R., Gelfand E., Glynn R.J., Goetsch M., Grégoire J., Grobbee D., Hessinger D., Hwang J.J., Jacoby D., Jadbabaie F., Jensen H.K., Johnson M., Jukema J.W., Kahan T., Karpov Y., Kastelein J.J.P., Koenig W., Lee C.W., Leiva Pons J.L., Lorenzatti A.J., Lotan C., Maggioni A.P., Manga P., Masiukiewicz U., McCullough L., McMurray J.J.V., McNamara R., McPherson C., Mellbin L., Miller M., Missault L., Montalescot G., Mosterd A., Mridha K., Murin J., Neaton J., Nicolau J.C., Nissen S.E., Noble S., O’Neill B., Piazza G., Pinto D., Ponikowski P., Powell C., Pride Y., Revkin J., Ridker P.M., Sandra Verónica Falconí Peláez, Sansing L.H., Santos R.D., Savolainen M., Savonitto S., Schiele F.N., Schindler J., Schwartz P.F., Shear C.L., Silverman I.E., Solar M., Soran H., Sritara P., Tarasenko L., Tardif J.C., Tökgozoğlu L., Urina M., Vrablik M., Wang E., Wei C., Welty F., White H.D., Wright R.S., Yunis C., Zannad F.Fuentes:googlescopusMortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
ArticleAbstract: Background: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily comparedPalabras claves:aspirin, Coronary artery disease, Mortality , Peripheral artery disease, rivaroxabanAutores:Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Connolly S.J., Dagenais G.R., Eikelboom J.W., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Maggioni A.P., Muehlhofer E., Sharma M., Shestakovska O., Yusuf S.Fuentes:googlescopusLong-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
ArticleAbstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheralPalabras claves:aspirin, Coronary artery disease, Peripheral artery disease, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.Fuentes:scopusRationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
ArticleAbstract: Background Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alPalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Ha J.W., Hart R.G., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Lanius V., Leong D.P., Lewis B.S., Liang Y., Liu L., Lonn E.M., Maggioni A.P., Metsarinne K.P., Misselwitz F., Moayyedi P., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yuan F., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusRationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
ArticleAbstract: Background: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patientsPalabras claves:Autores:Aguilar D., Aizenberg D., Allen P., Alvarez C., Alvarisqueta A., Amerena J., Baccaro C., Barkoudah E., BARTOLACCI I.P., Bentley-Lewis R., BORDONAVA A.P., Brahimi A., Bustamante Labarta M., CACCAVO A., Calella P., Cantero M., Charytan D., Chaturvedi N., Claggett B., Codutti R., Commendatore V., Costamagna O., Cuello J.L., Danilova L., Del Prato S., DeMets D., DIaz R., Dickstein K., Fasching P., Fernandez A., Finn P., Flynn A., GARCIA DURAN R.O., Gerstein H.C., Gomez Vilamajo O., Gorban De Lapertosa S., Granger C.B., GRINFELD D., Hartley L.H., Henderson G., Hermida S., Johnston P., Joseph J., Kaplan A., Køber L.V., Lagrutta M., Lawson F., Leon De La Fuente R., Lewis E.F., Licheri A., Lieberman P., LUCIARDI H.L., MACKINNON I.J., MAFFEI L.E., Maggioni A.P., Marino J., McMurray J.J.V., Montaña O., Novaretto L., O'Reilly E., Odutayo K., Orio S., Orlandini A., Oviedo A., Patel K., Patocchi C., Paul V., Pérez Manghi F., Petrie J., Pfeffer M.A., Pieber T., Ping L., Probstfield J.L., Raccah D., Rajesh V., Ramos H., Riddle M.C., Rolandi F., Rouleau J.L., Saa Zarandon R., Saavedra S.S., Sangla K., Scarpa A., Schattner M., SCHIAVI L.B., SCHYGIEL P.O., Solomon S.D., Tardif J.C., Trivi M., Ulla M., Urdiales P., Vallejos J., Van Gaal W., Vazir A., VICO M., Waisman F., Weinrauch L., Wu Y., Yan C. Duarte-Vera, Yeap B., Zuraw B.L.Fuentes:scopusRivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
ArticleAbstract: Background: Patients with peripheral artery disease have an increased risk of cardiovascular morbidiPalabras claves:Autores:Aboyans V., ABRANTES J.A., AHUAD GUERRERO R.A., ALBISU DI GENNERO J.P., Alings M., ALVAREZ M., Anand S.S., Avezum A.J., Bangdiwala S.I., Barbieri M., BARTOLACCI I.P., Bhatt D.L., BORDONAVA A.P., Bosch J.J., Branch K.R.H., CACCAVO A., CARDONA M., CARTASEGNA L.U.I.S., Chacón C., Chen E., Commerford P.J., Connolly S.J., COSTABEL J.P., CUADRADO J., Cuneo C.A., DEBONNAIRE P., DIaz R., DRAN R.D., DUJARDIN K.A.R.L., ECTOR B.A.V.O., Eikelboom J.W., ELEGEERT I.V.A.N., FERRE PACORA F.A., Fox K.A.A., GARCIA DURAN R.O., GARRIDO M., Gomez Vilamajo O., GONZALEZ COLASO P.D.C., GRINFELD D., GUZMAN L.U.I.S., Hart R.G., HASBANI E., HERNANDES M., HOFFER E., HOMINAL M.A., HRABAR A., IBANEZ SAGGIA L.M., INDIO DO BRASIL C., Ingaramo A., Kakkar A.K., Keltai K., Leong D.P., LEROY J.E.A.N., Lewis B.S., LITVAK BRUNO M.R., LUCIARDI H.L., LUQUEZ H.U.G.O., MACIN S.M., MACKINNON I.J., MAFFEI L.E., Maggioni A.P., Maia L.N., MAJUL C.R., MANENTI E., Misselwitz F., Montaña O., NANI S., Novaretto L., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, PELAGAGGE M.J., Pogosova N., Precoma D.B., Reis G., ROSSI DOS SANTOS F., ROSSI P., Rydén L.E., SALA J., SARAIVA J.O.S.E., SARJANOVICH R.J., SCHIAVI L.B., SCHROE H., SCHYGIEL P.O., Störk S., VAN DE BORNE P., VAN DEN HEUVEL P.A.U.L., Vanassche T., Varigos J.D., VENSENTINI N., Verhamme P.B., VICO M., Vinereanu D., VITA N.A., VOGEL D., VRANCKX P., Widimsky P., Yan Duarte, Yusuf S., ZAIDMAN C., Zhu J., ZIMMERMANN S.L.Fuentes:scopus